Loading
Springer Nature AG & Co. KGaA Stock: price and insider trades · Germany
No insider purchase over the last 90 days. The latest was filed 12 Jan 2026.
Springer Nature AG & Co. KGaA: what insiders have been doing
Springer Nature AG & Co. KGaA, classified in the Media & Communication sector, is a listed company based in Berlin, Germany, founded in 2015. Its insiders report their share dealings to BaFin. Between 18 October 2025 and 18 October 2026, 1 insider published 1 filing.
Not one open-market sale was filed. On the buying side, 1 insider reported 1 purchase totalling €95k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Those buying include 1 board member. At €95k, the purchase published on 12 January 2026 by Hirsch, Bernd is the largest of the period.
Compared with its exchange (287 companies, median 5 filings), a count of 1 filing is below the norm. Looking back to 2025, when coverage begins, insiders filed 1 purchase and 2 sales.
The last insider purchase was made public on 12 January 2026, 278 days ago.
Elsewhere in the same sector, our signals recently picked up insider purchases at Globalstar, Inc. and Liberty Latin America Ltd. These figures are compiled from regulatory filings published by BaFin. They describe what insiders did and are not a recommendation.
Insider Decl.
3
Thresholds
n/a
Buy Volume
€95,455
1 ops. · all time
Sell Volume
€292,441
2 ops. · all time
Who traded when
BuySaleRachel Jacobs3 sales
Bernd Hirsch1 buy
Since the insiders bought
- +12.5%Entry €18.22 · Close 14 Oct 2026 €20.50
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Springer Nature AG & Co. KGaA Buy (bullish), based on 8 analysts. Average price target: €26.14.
Fundamental score
Ranked 1,000 of 24,148 companies
80.0
score / 100
Value82
Quality78
FCF yld13%
Earn yld9.0%
EV/EBITDA7.1x
ROE17%
Gross mgn87%
Net mgn18%
Debt/EBITDA2.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€19.98
Analyst consensus
8 analystsBuy
€20.00Target €26.14(+31%)€32.40
Income statement
Revenue€1.9B
Gross profit€1.7B87% margin
EBITDA€772.6M40% margin
Net income€355.7M16.8% margin
Valuation
PER (trailing)12.0x
PER (forward)11.0x
P/Book2.0x
Balance sheet & cash
Market cap€4.0B
Total debt€1.5B
Free Cash Flow€520.2M
Debt / Equity72%
Profitability & ownership
ROE17.1%
ROA5.8%
% insiders85.4%
% institutions8.0%
Last declaration on 12 January 2026
Declarations3 total
5,199.09 shares@ €18.36100.0% of flowShareXETRAISIN DE000SPG1003BAFIN:40026865-1c1083760e04
Canonical exit: 7 Apr 2026 (T+90)
8,286.541 shares@ €21.0659.7% of flowShareXETRAISIN DE000SPG1003BAFIN:40026865
5,459.553 shares@ €21.6040.3% of flowShareXETRAISIN DE000SPG1003BAFIN:40026865-4206d0d33478
3 of 3 declarations
About Springer Nature AG & Co. KGaA
Springer Nature AG & Co. KGaA is one of the world’s leading publishers of research, health and education content. Listed in Germany on Xetra/Frankfurt (DAX/MDAX/SDAX), in the country Germany, the company is relevant to investors looking for exposure to a high-quality information services model with recurring demand, structural growth in open access, and strong long-term brand equity. The group was formed in May 2015 through the combination of Nature Publishing Group, Macmillan Education and Springer Science+Business Media, but its heritage goes back much further: Springer was founded in Berlin in 1842, Macmillan in 1843, and Nature was first published in 1869. Today, Springer Nature is a globally recognized academic publisher with flagship brands including Springer, Nature Portfolio, BMC, Palgrave Macmillan and Scientific American.
Its business model is built around three main segments. Research publishes scientific journals, books and digital platforms for researchers, universities, libraries and research funders. Health provides medical and pharmaceutical information products and services for healthcare professionals. Education covers textbooks, digital learning content and educational solutions used by schools, universities and teachers. Revenue therefore comes from a mix of subscriptions, open access publishing, licensing, book sales and technology-enabled services.
Read moreShow less
From a competitive standpoint, Springer Nature is one of the strongest global players in scholarly publishing. Its advantages include premium brands, deep editorial expertise, a broad content portfolio and an increasingly effective ability to monetise the shift toward open access. The company is also investing heavily in technology and AI across the publishing workflow, including manuscript screening, editorial evaluation, peer-review support and research integrity tools. That should help improve author experience, operational efficiency and retention while strengthening the moat around its publishing ecosystem.
Geographically, Springer Nature has a truly international footprint, with major hubs in Berlin, London and New York, alongside a broad network of editorial, commercial and technology teams around the world. Its corporate home and historic roots are in Germany, which makes it a notable German listed asset for francophone investors seeking a defensive but innovation-linked business.
Recent highlights include a strong 2025 performance, with revenue growth and continued momentum in Research, supported by open access. In early 2026, the group launched new editorial initiatives such as the Nature Progress series and highlighted broader deployment of AI tools across publishing. Overall, Springer Nature continues to combine academic heritage, digital transformation and disciplined execution.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
